Watertown, Massachusetts-based Triveni Bio Inc., a clinical-stage biotechnology company developing antibody therapies for immunological and inflammatory disorders, has closed a Triveni Bio Series C funding round of USD 65 million to support expanded clinical development of its TRIV-573 bispecific antibody and broader pipeline growth.
The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital alongside additional existing investors. In conjunction with the Triveni Bio financing, Evan Rachlin, M.D., Co-Founder and Managing Partner at Ascenta Capital, has joined the company's Board of Directors.
The central asset being advanced via the financing is TRIV-573, a half-life extended bispecific antibody designed to simultaneously inhibit KLK5/7 and IL-13, two pathways implicated in atopic dermatitis. The approach aims to address both skin barrier dysfunction and Th2-driven inflammation within a single molecule, with the company planning to initiate a Phase II proof-of-concept study in moderate-to-severe atopic dermatitis later in 2026. Triveni also said the funding will support exploration of KLK5/7 biology in other barrier-related disorders beyond atopic dermatitis.
The company's most advanced program is TRIV-509, a KLK5/7-targeting antibody currently in Phase II testing for atopic dermatitis, with topline data expected by the end of 2026. The Series C proceeds will primarily support TRIV-573, a next-generation bispecific antibody targeting both KLK5/7 and IL-13 that is expected to enter Phase II testing later this year. TRIV-573 is designed as a second-generation asset that layers IL-13 blockade onto the KLK5/7 mechanism, with preclinical data indicating additive activity when the two pathways are combined.